Clinical trial
Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With…
NCT00016263 · Genta Incorporated, Industry · Completed
Key facts
| NCT number | NCT00016263 |
|---|---|
| Title | Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma |
| Official title | Randomized Study Of Dacarbazine Versus Dacarbazine Plus G3139 (Bcl-2 Antisense Oligonucleotide) In Patients With Advanced Malignant Melanoma |
| Lead sponsor | Genta Incorporated, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological, Drug |
| Interventions | oblimersen sodium, dacarbazine |
| Start date | Jul 1, 2000 |
| Completion | Dec 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 6, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: